Trials / Active Not Recruiting
Active Not RecruitingNCT04184050
Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001)
A Phase 1 Open-label, Multicenter, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of HPN217 in Patients With Relapsed/Refractory Multiple Myeloma
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 100 (actual)
- Sponsor
- Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Researchers want to learn if MK-4002 (also known as HPN217) can treat relapsed or refractory multiple myeloma (RRMM). The goals of this study are to learn about the safety of different doses of MK-4002 and how well people tolerate them. Researchers also want to learn what happens to different doses of MK-4002 in a person's body over time.
Conditions
- Multiple Myeloma in Relapse
- Multiple Myeloma
- Multiple Myeloma of Bone
- Multiple Myeloma With Failed Remission
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK-4002 | IV infusion |
Timeline
- Start date
- 2020-04-13
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
- First posted
- 2019-12-03
- Last updated
- 2025-12-05
Locations
12 sites across 3 countries: United States, France, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04184050. Inclusion in this directory is not an endorsement.